We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

5 hedge funds and large institutions have $2.49M invested in Hepion Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 4 → 5 (+1)

9% less capital invested

Capital invested by funds: $2.75M → $2.49M (-$255K)

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$569K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$284K

Top Sellers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$8K
2
MCIA
Mountain Capital Investment Advisors
Colorado
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$933K +$284K +1 +25%
AFM
2
Anson Funds Management
Texas
$446K +$569K +2 New
HighTower Advisors
3
HighTower Advisors
Illinois
$374K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$113K – – –
Barclays
5
Barclays
United Kingdom
$106K – – –
JP Morgan Chase
6
JP Morgan Chase
New York
$72K – – –
VF
7
Virtu Financial
New York
$65K – – –
PFS
8
Prospera Financial Services
Texas
$57K – – –
CS
9
Credit Suisse
Switzerland
$54K – – –
Citadel Advisors
10
Citadel Advisors
Florida
$52K – – –
Northern Trust
11
Northern Trust
Illinois
$39K – – –
PIA
12
Phoenix Investment Adviser
New York
$36K – – –
Morgan Stanley
13
Morgan Stanley
New York
$26K – – –
TSS
14
Two Sigma Securities
New York
$26K – – –
BlackRock
15
BlackRock
New York
$22K – – –
Bank of Montreal
16
Bank of Montreal
Ontario, Canada
$18K – – –
Bank of New York Mellon
17
Bank of New York Mellon
New York
$13K – – –
CC
18
Cornerstone Capital
California
$10K – – –
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$8K – – –
ISL
20
Ingalls & Snyder LLC
New York
$5K – – –
LPL Financial
21
LPL Financial
California
$5K – – –
FFA
22
First Foundation Advisors
California
$4K – – –
UBS Group
23
UBS Group
Switzerland
$4K – – –
IWM
24
IHT Wealth Management
Illinois
$2K – – –
BWA
25
BDO Wealth Advisors
Florida
$1K – – –
1
2

HEPA Hedge Fund Activity: Q4 2017 in Review

5 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2017, worth a combined $2.49M — down 9.3% from $2.75M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new HEPA positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $569K. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $8K.

  • 5 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2017, up from 4 in Q3 2017.
  • Funds reported $2.49M of Hepion Pharmaceuticals stock for Q4 2017, down 9.3% quarter-over-quarter.
  • 1 fund opened new Hepion Pharmaceuticals positions in Q4 2017 and 0 closed out, a net change of +1 holder.
  • The largest Hepion Pharmaceuticals buyer in Q4 2017 was Anson Funds Management, an estimated $569K added.
  • The largest Hepion Pharmaceuticals seller in Q4 2017 was Cambridge Investment Research Advisors, an estimated $8K sold.

Based on aggregated 13F filings for Q4 2017.